GPER has also been implicated in other cancers as either a pro- or anti-tumorigenic factor and observations, specifically in the melanoma field, have led to the initiation of a Phase I clinical trial for a GPER-targeted drug (NCT04130516) [21,22,23]. The gene discussed is GPER1; the disease is cancer.